
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
almost 26 years ago
Participating Facultyalmost 26 years ago
Continuing Medical Education Quiz





